FrancophonIA/ELRC3.0 huggingface dataset:
English: Also seen commonly but with less severe effects, were localised or general pain, nausea, flatulence, tachypnea, polydipsia, fever, urinary tract infection, increased bilirubin, increased creatinine.
Danish: Almindeligt forekommende bivirkninger med mindre alvorlig indvirkning inkluderer: lokaliseret eller generel smerte, kvalme, luft i tarmene, hurtig vejrtrækning, sygeligt forøget tørst, feber, urinvejsinfektion, øget galdefarvestof, øget kreatinin.
English: Excipients:
Danish: Filmovertræk:
English: Pharmacotherapeutic group: Antineoplastic Agents - Protein-kinase inhibitors ATC vet code: QL01XE91
Danish: ATCvet-kode: QL01XE91
English: • Three dogs had seizure-like activity; however, relation to treatment could not be established.
Danish: • Tre hunde havde krampelignende aktivitet.
English: There were other side effects that are seen commonly (more than 1 but less than 10 animals in 100 animals treated) which have severe effects, these are vomiting, diarrhoea, anorexia, lethargy, dehydration, skin necrosis, fever, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding and ulcers, nausea, septicaemia, weight loss, increased alanine aminotransferase and decreased haematocrit.
Danish: Andre alvorlige bivirkninger, som er almindeligt set (flere end 1, men færre end 10 dyr af 100 behandlede dyr) inkluderer: opkastning, diarré, spisevægring, sløvhed, væskemangel, vævshenfald af hud, feber, blod i afføring/blodig diarré/maveblødning og mavesår, kvalme, blodforgiftning, vægttab, øget alaninaminotransferase og nedsat indhold af røde blodlegemer i blodet.
English: • Diarrhoea, neutropenia, weight loss, blood in faeces/hemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting; lameness / musculoskeletal disorder, dehydration, dermatitis, pruritus; increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
Danish: • Diarré, neutropeni, vægttab, blod i fæces/hæmoragisk diarré/gastrointestinal blødning, anoreksi, letargi, opkastning; halthed/muskuloskeletale lidelser, dehydrering, dermatitis, pruritus; øget alaninaminotransferase, trombocytopeni, nedsat albumin-, nedsat hæmatokrit.
English: • Vomiting, diarrhoea, anorexia, lethargy, dehydration, pyrexia, blood in faeces/haemorrhagic diarrhoea/gastrointestinal bleeding, duodenal ulceration, nausea, septicaemia, skin necrosis, weight loss; increased alanine aminotransferase, decreased haematocrit.
Danish: • Opkastning, diarré, anoreksi, letargi, dehydrering, pyreksi, blod i fæces/hæmoragisk diarré/gastrointestinal blødning, duodenalsår, kvalme, septikæmi, hudnekrose, vægttab; øget alaninaminotransferase, nedsat hæmatokrit.
English: • Blood urea nitrogen <1.5 X upper normal limit
Danish: • Urinkvælstof i blodet <1,5 gange øvre normalgrænse
English: If gastrointestinal ulceration is suspected, whether or not due to Palladia or to mast cell tumour degranulation, stop the administration of Palladia and treat appropriately.
Danish: Administration af Palladia skal ophøre og passende behandling iværksættes, hvis der er mistanke om gastrointestinal ulceration, uanset om det skyldes Palladia eller degranulering af mastcelletumorer.
English: Discontinue treatment until >1.5 g/dl and clinical signs normal, then decrease dose by 0.5 mg/kg
Danish: Afbryd behandling indtil >1,5 g/dl og de kliniske tegn er normaliseret.
English: Tablet coating: Palladia 10 mg tablets: Macrogol, Titanium dioxide (E171), Lactose monohydrate, Triacetin, Hypromellose, Indigo Carmin Lake (E132)
Danish: Macrogol, titandioxid (E171), lactosemonohydrat, triacetin, hypromellose, indigocarmin Lake (E132)
English: • There were two further deaths; however, relation to treatment could not be established.
Danish: • Der forekom yderligere to dødsfald.
English: Some very common (more than 1 in 10 animals treated displaying adverse reaction(s)) adverse reactions associated with Palladia tablets are weight loss, diarrhoea, neutropenia (low number of white blood cells), blood in faeces/ haemorrhagic diarrhoea/gastrointestinal bleeding, anorexia, lethargy, vomiting, lameness/ musculoskeletal disorder, dehydration, dermatitis, pruritus (skin irritation/scratching), increased alanine aminotransferase, thrombocytopenia, decreased albumin, decreased haematocrit.
Danish: Nogle meget almindelige (flere end 1 ud af 10 behandlede dyr, der viser bivirkninger i løbet af en behandling) bivirkninger, som forbindes med Palladia-tabletter, er vægttab, diarré, neutropeni (lavt antal hvide blodlegemer), blod i afføring/blodig diarré/blødning i mavetarmkanalen, spisevægring, sløvhed, opkastning; halthed/forstyrrelser i bevægeapparatet, væskemangel, hudbetændelse, pruritus, (hudirritation, kløe); øget alaninaminotransferase, nedsat antal af blodplader, nedsat albumin, nedsat indhold af røde blodlegemer i blodet.
English: Discontinue treatment until ≤3X upper normal limit,
Danish: Afbryd behandling indtil ≤3X øvre normalgrænse, seponer hepatoksiske lægemidler, hvis anvendt.
English: Each tablet contains 10 mg toceranib (as toceranib phosphate).
Danish: Hver tablet indeholder 10 mg toceranib (som toceranibphosphat).
English: Keep children away from faeces, urine or vomit of treated dogs.
Danish: Børn skal holdes væk fra fæces, urin eller opkast fra behandlede hunde.
English: Each tablet contains 50 mg toceranib (as toceranib phosphate).
Danish: Hver tablet indeholder 50 mg toceranib (som toceranibphosphat).
English: Each tablet contains 15 mg toceranib (as toceranib phosphate).
Danish: Hver tablet indeholder 15 mg toceranib (som toceranibphosphat).
English: Manufacturer responsible for the batch release:
Danish: FREMSTILLER ANSVARLIG FOR BATCHFRIGIVELSE
English: Palladia 10 mg tablets for dogs.
Danish: Palladia 10 mg tabletter til hund.
English: Discontinue treatment until >26%, then decrease dose by 0.5 mg/kg
Danish: Nedsæt derefter dosis med 0,5 mg/kg
English: Palladia 15 mg tablets for dogs.
Danish: Palladia 15 mg tabletter til hund.
English: Palladia 50 mg tablets for dogs.
Danish: Palladia 50 mg tabletter til hund.
English: Palladia 10 mg film-coated tablets for dogs.
Danish: Palladia 10 mg filmovertrukne tabletter til hund.
English: Palladia 50 mg film-coated tablets for dogs.
Danish: Palladia 50 mg filmovertrukne tabletter til hund.
English: Palladia 15 mg film-coated tablets for dogs.
Danish: Palladia 15 mg filmovertrukne tabletter til hund.
English: Discontinue treatment until >1000/µl and clinical signs normal, then decrease dose by 0.5 mg/kg
Danish: Afbryd behandling indtil >1000/ µl og kliniske tegn er normaliseret.
English: discontinue hepatotoxic drugs, if used, then decrease dose by 0.5 mg/kg
Danish: Nedsæt derefter dosis med 0,5 mg/kg.
English: Discontinue treatment until <1.25 X upper normal limit, then decrease dose by 0.5 mg/kg
Danish: Afbryd behandling indtil <1,25 X øvre normalgrænse.
English: Discontinue treatment and institute supportive care until resolution of all clinical signs of blood in stool, then decrease dose by 0.5 mg/kg
Danish: Afbryd behandling og iværksæt understøttende behandling indtil der ikke længere er kliniske tegn på blod i afføring.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Palladia 10 mg film-coated tablets for Dogs
Danish: Palladia 10 mg filmovertrukne tabletter til hund Palladia 15 mg filmovertrukne tabletter til hund Palladia 50 mg filmovertrukne tabletter til hund
English: • breast cancer.
Danish: • Brystkræft.
English: The full EPAR for Docetaxel Teva Pharma can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Danish: Den fuldstændige EPAR for Docetaxel Teva Pharma findes på agenturets websted på ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: • non-small cell lung cancer.
Danish: • Ikke-småcellet lungekræft.
English: It can also be used with cisplatin (another anticancer medicine) in patients who have not yet received any treatment for their cancer;
Danish: Det kan også bruges sammen med cisplatin (et andet lægemiddel mod kræft) til patienter, der endnu ikke har fået nogen behandling mod deres kræftsygdom.
English: The dose, duration of treatment and the medicines it is used with depend on the type of cancer being treated.
Danish: Dosis, behandlingsvarighed og anvendelse sammen med andre lægemidler afhænger af den pågældende kræfttype.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Docetaxel Teva Pharma.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Docetaxel Teva Pharma.
English: • prostate cancer, when the cancer does not respond to hormonal treatment.
Danish: • Prostatakræft, når hormonbehandling ikke virker på sygdommen.
English: For more information about treatment with Docetaxel Teva Pharma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Docetaxel Teva Pharma, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: Docetaxel Teva Pharma is only used when the neutrophil count (the level of a type of white blood cell in the blood) is normal (at least 1,500 cells/mm3).
Danish: Docetaxel Teva Pharma må kun bruges, når neutrofiltallet (en type hvide blodlegemer) er mindst 1 500 celler/mm3.
English: This means that Docetaxel Teva Pharma is similar to a ‘reference medicine' already authorised in the European Union (EU) called Taxotere.
Danish: Det betyder, at Docetaxel Teva Pharma er identisk med et ‘referencelægemiddel', der allerede er godkendt i Den Europæiske Union, og som hedder Taxotere.
English: Docetaxel Teva Pharma is given as a one-hour infusion every three weeks.
Danish: Docetaxel Teva Pharma gives hver tredje uge ved en infusion, der varer en time.
English: Docetaxel blocks the ability of cells to destroy the internal ‘skeleton' that allows them to divide and multiply.
Danish: Docetaxel blokerer cellers evne til at nedbryde det indvendige celleskelet og dermed deres evne til at dele og formere sig.
English: No additional studies were needed as Docetaxel Teva Pharma is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Taxotere.
Danish: Der krævedes ingen supplerende undersøgelser, eftersom Docetaxel Teva Pharma er et generisk lægemiddel, der indgives ved infusion og indeholder det samme aktive stof som referencelægemidlet Taxotere.
English: Docetaxel Teva Pharma is used with prednisone or prednisolone (anti-inflammatory medicines);
Danish: Docetaxel Teva Pharma anvendes sammen med prednison eller prednisolon (antiinflammatoriske lægemidler).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Docetaxel Teva Pharma to Teva Pharma B.V. on 21 January 2011.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Docetaxel Teva Pharma til Teva Pharma B.V.
English: Docetaxel Teva Pharma is used to treat the following types of cancer:
Danish: Docetaxel Teva Pharma anvendes til behandling af følgende kræftformer:
English: Because Docetaxel Teva Pharma is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Danish: Da Docetaxel Teva Pharma er et generisk lægemiddel, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet.
English: The CHMP concluded that, in accordance with EU requirements, Docetaxel Teva Pharma has been shown to be comparable to Taxotere.
Danish: CHMP konkluderede, at Docetaxel Teva Pharma i overensstemmelse med EU's krav har vist sig at være sammenligneligt med Taxotere.
English: The company has provided data from the published literature on docetaxel.
Danish: Virksomheden har fremlagt data fra faglitteraturen om docetaxe.
English: Docetaxel Teva Pharma is a medicine that contains the active substance docetaxel.
Danish: Docetaxel Teva Pharma er et lægemiddel, der indeholder det aktive stof docetaxel.
English: The active substance in Docetaxel Teva Pharma, docetaxel, belongs to the group of anticancer medicines known as the taxanes.
Danish: Det aktive stof i Docetaxel Teva Pharma , docetaxel, tilhører en gruppe kræftlægemidler, der kaldes taxaner.
English: Docetaxel Teva Pharma should be used in wards specialising in chemotherapy (using medicines to treat cancer) under the supervision of a doctor who is qualified in the use of chemotherapy.
Danish: Docetaxel Teva Pharma bør kun anvendes på afdelinger, der er specialiseret i kemoterapi, under overvågning af en læge, der er specialiseret i brug af kemoterapi.
English: Docetaxel Teva Pharma is a ‘generic medicine'.
Danish: Docetaxel Teva Pharma er et ‘generisk lægemiddel'.
English: What are the benefits and risks of Docetaxel Teva Pharma?
Danish: Hvilken fordel og risiko er der forbundet med Docetaxel Teva Pharma?
English: Other information about Docetaxel Teva Pharma
Danish: Andre oplysninger om Docetaxel Teva Pharma:
English: It is available as a concentrate and a solvent that are made up into a solution for infusion (drip into a vein).
Danish: Docetaxel Teva Pharma er et koncentrat og en solvens, der blandes til en opløsning til infusion (dråbetilførsel i en vene).
English: The company also showed that the Docetaxel Teva Pharma solution for infusion has comparable quality to that of Taxotere.
Danish: Derudover fremlagde virksomheden undersøgelsesresultater til påvisning af, at kvaliteten af Docetaxel Teva Pharma infusionsopløsning svarer til kvaliteten af Taxotere.
English: Docetaxel Teva Pharma can be used on its own after other treatments have failed.
Danish: Docetaxel Teva Pharma kan bruges som eneste behandling, når andre lægemidler har været uden virkning.
English: The Committee recommended that Docetaxel Teva Pharma be given marketing authorisation.
Danish: Udvalget anbefalede udstedelse af markedsføringstilladelse for Docetaxel Teva Pharma.
English: Why has Docetaxel Teva Pharma been approved?
Danish: Hvorfor blev Docetaxel Teva Pharma godkendt?
English: This is a summary of the European public assessment report (EPAR) for Docetaxel Teva Pharma.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR).
English: Dexamethasone (an anti-inflammatory medicine) should also be given to the patient, starting on the day before the Docetaxel Teva Pharma infusion.
Danish: Dagen før infusionen af Docetaxel Teva Pharma gives desuden dexamethason (et antiinflammatorisk lægemiddel) til patienten.
English: How has Docetaxel Teva Pharma been studied?
Danish: Hvordan blev Docetaxel Teva Pharma undersøgt?
English: What is Docetaxel Teva Pharma?
Danish: Hvad er Docetaxel Teva Pharma?
English: How is Docetaxel Teva Pharma used?
Danish: Hvordan anvendes Docetaxel Teva Pharma?
English: What is Docetaxel Teva Pharma used for?
Danish: Hvad anvendes Docetaxel Teva Pharma til?
English: How does Docetaxel Teva Pharma work?
Danish: Hvordan virker Docetaxel Teva Pharma?
English: Therefore, these recommendations are only tentative.
Danish: Derfor er disse rekommendationer kun tentative.
English: below 15*
Danish: under 15*
English: Very common (>1/10); Common (>1/100, <1/10); Uncommon (>1/1,000 <1/100); Rare (>1/10,000 <1/1,000); Very Rare (<1/10,000)
Danish: Meget almindelig (>1/10); Almindelig (>1/100, <1/10); Ikke almindelig (>1/1,000 <1/100); Sjælden (>1/10,000 <1/1,000); Meget sjælden (<1/10,000)
English: Lot {number}
Danish: lot {nummer}
English: In severe cases these may lead to shock and death.
Danish: I alvorlige tilfælde kan dette medføre chok og dødsfald.
English: above 60 (530)*
Danish: over 6.0 (530)*
English: Standard recommendations
Danish: Standardrekommendationer
English: Initial intravenous bolus:
Danish: Initial intravenøs bolus:
English: - The aPTT should be monitored at least once daily.
Danish: - APTT skal kontrolleres mindst 1 gang daglig.
English: avoid or STOP infusion !
Danish: undgå eller AFBRYD infusionen!
English: No specific dosage adjustment is made for elderly patients.
Danish: Ingen specifik dosisjustering bliver foretaget for ældre patienter.
English: - Paediatric Use: Safety and effectiveness in paediatric patients have not been established.
Danish: - Pædiatrisk brug: Sikkerheden og effektiviteten til behandling af pædiatriske patienter er ikke blevet fastsat.
English: This is valid up to a body weight of 110 kg.
Danish: Dette gælder for en legemsvægt op til 110 kg.
English: Initial dosage
Danish: Initial dosering
English: The optimal dose regimen of Refludan in these circumstances is not known.
Danish: Refludans optimale dosering under disse omstændigheder kendes ikke.
English: Age alone causes a 7 % reduction in clearance from the age of 30 to 70 years.
Danish: Alder alene bevirker en 7 % reduktion i clearance i aldersgruppen 30-70 år.
English: Do not store above 25C.
Danish: Må ikke opbevare over 25º C.
English: The majority of the difference in clearance between young and elderly patients is due to the differences in renal function.
Danish: Størstedelen af forskellen i clearance mellem unge og ældre patienter skyldes forskelle i nyrefunktionen.
English: Intravenous injection is to be carried out slowly.
Danish: Den intravenøse injektion skal foretages langsomt.
English: General recommendations - Reconstitution and further dilution must be carried out under sterile conditions.
Danish: Almene anbefalinger - Rekonstituering og yderligere fortynding skal ske under sterile forhold.
English: About 35 % of the dose is excreted as unchanged compound.
Danish: Ca. 35 % af dosis udskilles uændret.
English: Normally, the dosage depends on the patient's body weight.
Danish: Dosis afhænger sædvanligvis af patientens legemsvægt.
English: • CONDITIONS OR RESTRICTIONS WITH REGARD TO SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Danish: BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE SIKKER OG EFFEKTIV ANVENDELSE AF DET MEDICINSKE PRODUKT
English: Further dilution is necessary prior to use.
Danish: Yderligere fortynding er nødvendig før brug.
English: Your doctor will determine and control the dosage and duration of your treatment with Refludan according to your clinical condition, your body weight, and certain laboratory values.
Danish: Deres læge vil bestemme og kontrollere dosis og varigheden af behandlingen med Refludan afhængigt af Deres kliniske tilstand, legemsvægt og visse laboratorieværdier.
English: The specific activity of lepirudin is approximately 16,000 ATU/mg.
Danish: Den specifikke lepirudin-aktivitet er ca. 16.000 ATU/mg.
English: Read all of this leaflet carefully before you start using this medicine.
Danish: Læs hele denne indlægsseddel grundigt, inden De begynder at bruge medicinen.
English: Refludan is available in packs of 1 or 10 vials.
Danish: Refludan fås i pakker på 1 eller 10 hætteglas.
English: The infusion rate must be reduced according to table 1.
Danish: Infusionshastigheden bør reduceres i henhold til tabel 1.
English: The aPTT should be determined again 4 hours later.
Danish: APTT bør bestemmes igen 4 timer senere.
English: There is currently no information available on the use of Refludan during lactation.
Danish: På nuværende tidspunkt er der ingen tilgængelige informationer om brugen af Refludan under amning.
English: Date of first authorisation: 13-03-1997 Date of last renewal: 05-03-2007
Danish: Dato for første markedsføringstilladelse: 13-03-97 Dato for sidste fornyelse af tilladelsen: 05-03-07
English: Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine.
Danish: Graviditet og amning Spørg Deres læge eller apotek til råds, før De tager nogen form for medicin.
English: Its mode of action is independent of antithrombin III.
Danish: Virkningsmekanismen er uafhængig af antithrombin III.
English: The polypeptide composed of 65 amino acids has a molecular weight of 6979.5 Dalton.
Danish: Polypeptidet består af 65 aminosyrer og har en molekylevægt på 6979,5 Dalton.
English: The intended maintenance dose should be started with no loading dose.
Danish: Der bør begyndes med den påtænkte vedligeholdelsesdosis uden forudgående belastningsdosis.
English: If you have the impression that the effect of Refludan is too strong or too weak, talk to your doctor or pharmacist.
Danish: Hvis De har en følelse af at effekten af Refludan er for stærk eller for svag, så tal med Deres læge eller apoteket herom.
English: The majority of undesirable effects experienced by patients treated with Refludan were generally related to bleeding (>1/10).
Danish: Hovedparten af de bivirkninger, som patienterne fik under behandlingen med Refludan var generelt relateret til blødning (>1/10).
English: - The perfusor syringe must be changed at least every 12 hours after the start of the infusion.
Danish: - Perfusionssprøjten skal skiftes senest hver 12. time efter infusionens påbegyndelse.
English: - The preparation should be warmed to room temperature before administration.
Danish: - Præparatet bør opvarmes til stuetemperatur inden administration.
English: Hot flushes Shock including fatal shock
Danish: Hedeture Chok inklusive fatalt chok
English: At restart, the infusion speed should be decreased by 50 % (no additional intravenous bolus should be administered).
Danish: Når infusionen genoptages, bør infusionshastigheden nedsættes med 50 % (yderligere intravenøst bolus bør ikke administreres).
English: Adjusted infusion rate [% of original dose]
Danish: Justeret infusionshastighed [% af oprindelig dosis]
English: The diagnosis should be confirmed by the HIPAA (heparin induced platelet activation assay) or an equivalent test.
Danish: Diagnosen skal verificeres med HIPAA (heparin induced platelet activation assay) eller tilsvarende test.
English: Therefore, alternative treatment options must be considered before the decision to re-expose a patient to Refludan.
Danish: Derfor bør alternative behandlingsmuligheder overvejes, før det besluttes at genbehandle patienter med Refludan.
English: Since the risk of serious bleeding is considerable in this situation, the dosage of Refludan should be substantially reduced.
Danish: Da risikoen for alvorlig blødning i disse tilfælde er betragtelig, skal Refludandosis reduceres væsentligt.
English: Therefore, strict monitoring of aPTT is necessary also during prolonged therapy.
Danish: Derfor er en stram kontrol af APTT nødvendig også ved længere behandling.
English: - Elderly: Patients of advanced age have an increased risk of bleeding complications with anticoagulation.
Danish: - Ældre: Patienter af en høj alder har en forøgede risiko for blødningskomplikationer med antikoagulation.
English: Both, excretion and metabolism take place in the kidney, and about 45 % of the dose administered is detectable in the urine.
Danish: Både ekskretion og metabolisme finder sted i nyrerne, og ca. 45 % af den indgivne dosis kan påvises i urinen.
English: Monitoring and modification of the Refludan dosage regimen
Danish: Monitorering og justering af Refludandosering
English: Very common (at least 1 in 10 people) - Bleeding
Danish: Meget almindelige (mindst 1 ud af 10 patienter) - Blødning
English: This leaflet was last approved on {date}
Danish: Denne indlægsseddel blev senest godkendt den {dato}
English: Refludan is an antithrombotic medicine.
Danish: Refludan er et antithrombotisk lægemiddel.
English: Cough Stridor Dyspnea
Danish: Hoste Stridor Dyspnø
English: As these reactions are immune-mediated, patients with recent exposure to hirudin or hirudin analog may be at an increased risk.
Danish: Da disse reaktioner er immunmedierede, kan patienter, der for nylig har været behandlet med hirudin eller hirudinanaloger, have en øget risiko.
English: WHAT REFLUDAN IS AND WHAT IT IS USED FOR
Danish: REFLUDANS VIRKNING OG HVAD DE SKAL BRUGE DET TIL